BCL2L1 and cancer: These data are consistent with the expression data supporting the use of the Bcl-xL-sparing ABT-199 in MYCN-amplified neuroblastoma (Figure 3A) and the ability of ABT-199 to induce apoptosis in these cancers (Figure 3B).